Research Article
Synergistic Antitumor Effect of Doxorubicin and Tacrolimus (FK506) on Hepatocellular Carcinoma Cell Lines
Figure 1
Cell viability %. Huh7 (a) and HepG2 (b) cell lines growth curves (CR) after doxorubicin, tacrolimus, and their combination treatment for 48 h. On the -axis are showed the different drugs concentrations (DC): 1 (no drugs), 2 (dox: 0.21 μM; tacr: 0.013 μM), 3 (dox: 0.42 μM; tacr: 0.026 μM), 4 (dox: 0.85 μM; tacr: 0.052 μM), 5 (dox: 1.7 μM; tacr: 0.1 μM), 6 (dox: 3.4 μM; tacr: 0.2 μM), and 7 (dox: 6.8 μM; tacr: 0.4 μM) for Huh7 and 1 (no drugs) 2 (dox: 0.09 μM; tacr: 0.002 nM), 3 (dox: 0.18 μM; tacr: 0.006 nM), 4 (dox: 0.37 μM; tacr: 0.047 nM), 5 (dox: 0.75 μM; tacr: 0.095 nM), 6 (dox: 1.5 μM; tacr: 0.18 nM), and 7 (dox: 3 μM; tacr: 0.36 nM) for HepG2; on the -axis: cell growth rate (CR).
